I don't think it's changed that much, hence my suggestions this morning around both enshrining a requirement for sex and gender analysis but also trying to now move to some kind of richer framework for the evaluation of drugs prior to their approval, because I think we can make some prediction. If we say we know this drug is going to be used in 70- and 80-year-old ladies, that's who should be in the trial. If we think it's going to be used in nine-year-olds, that's who should be in the trial. It does change the way we do business, for sure, but I really agree with Bruce. We need to take the approach of a public health and population health management process.
I have to say as I think about this that the burdens on industry on managing all of this also seem somewhat unfair. We need to think of a system that runs from a public health process, that we're producing data and developing research and processes that actually are a seamless continuum, that look like a program, not a bunch of band-aids stuck together.